SavedAdd your journal

Journals / Retina-Vitreus / 2017 / Cilt: 26 - Sayı: 0

Clinical Features and Spectral Domain Optical Coherence Tomography Findings in Vogt- Koyanagi-Harada Syndrome: A Case Series

Vogt-Koyanagi-Harada Sendromunda Klinik Özellikler ve Spektral Domain Optik koherens Tomografi Bulguları: Olgu Serisi

Seher SARITEPE İMRE
Melike BALIKOĞLU YILMAZ
Erdinç AYDIN
Emine Deniz EĞRİLMEZ
Berkay AKMAZ
Pages
287–295
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

VKH cases should be followed closely with regard to possible complications and recurrence.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We aimed to evaluate the clinical features and treatment results in 4 cases with Vogt-Koyanagi-Harada syndrome (VKH).
📊
Key Findings & Data:Four fe- male cases’age range was 33-58 years, follow-up duration 8 to 49 months.
💡
Conclusion & Impact:VKH cases should be followed closely with regard to possible complications and recurrence.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

We aimed to evaluate the clinical features and treatment results in 4 cases with Vogt-Koyanagi-Harada syndrome (VKH). Four fe- male cases’age range was 33-58 years, follow-up duration 8 to 49 months. All cases had bilateral involvement. Auditory compla- ints were available in three cases (hearing loss in 1 case, tinnitus in 2 cases). All cases were assessed by spectral domain optical coherence tomography, fl uorescein angiography and ultrasonog- raphy. Three patients were classified as "incomplete VKH" and one as "probable VKH”. Baseline visual acuity ranged from 2/20 to 3/20 in the RE and from 2/20 to 4/20 in the LE. All cases had bilateral anterior uveitis and exudative retinal detachment. Op- tic disc edema was also present in three cases. All patients were treated with high-dose corticosteroid therapy. In addition, cyc- losporine was administered to two cases and azathioprine to one case. Final visual acuity ranged from light perception to 20/20 in the RE and from 12/20 to 20/20 in the LE. During the follow-up, recurrence was observed twice in 1 case; choroidal neovascular membrane in 1 case, pupillary block, neovascular glaucoma and cataract in 1 case and secondary glaucoma in 1 case. Visual loss could be prevented by early diagnosis and treatment in VKH pa- tients. Corticosteroid is eff ective in treatment of VKH. Immuno- suppressive drugs could be useful in patients with a chronic VKH refractory to corticosteroid or who suff er severe adverse eff ects with corticosteroid. VKH cases should be followed closely with regard to possible complications and recurrence.

Özet

Vogt-Koyanagi-Harada sendromu (VKH) nedeniyle takip edilen 4 hastanın klinik özelliklerini ve tedavi sonuçlarını değerlendirme- yi amaçladık. Dört kadın hastanın yaşları 33-58 yaş, takip süre- leri 8-49 ay arasında değişmekteydi. Olguların tümünde bilateral tutulum mevcuttu. İşitsel şikâyetler üç olguda (1 olguda işitme azlığı, 2 olguda çınlama) mevcuttu. Olguların tümü spektral do- main optik koherens tomografi, fundus fl oresein anjiyografisi ve ultrasonografi ile değerlendirildi. Üç olgu “tam olmayan” ve bir olgu da “muhtemel” VKH olarak sınıfl andırıldı. Tüm olgularda bilateral ön üveit ve eksüdatif retina dekolmanı mevcuttu. Op- tik disk ödemi 3 olguda bulunmaktaydı. Tüm olgular yüksek doz kortikosteroid tedavisi ile tedavi edildi. İlaveten iki olguya siklosporin, birine azatioprin verildi. Takiplerde 1 olguda iki kez nüks izlendi, 1 olguda koroidal neovasküler membran, 1 olguda pupiller blok, neovasküler glokom ve katarakt ve 1 olguda sekon- der glokom gelişti. Vogt-Koyanagi-Harada sendromlu olgularda erken tanı ve tedavi ile görme kaybı engellenebilir. Sendromun tedavisinde kortikosteroidler etkili olup; kronik, kortikosteroid tedavisine dirençli ve şiddetli kortikosteroid yan etkileri gelişen olgularda immunsupresif ilaçlar faydalı olabilmektedir. Olası komplikasyonlar ve nüksler açısından VKH’lu hastalar yakın ta- kip edilmelidir.

🔖

Cite This Article

İMRE, S. S., YILMAZ, M. B., AYDIN, E., EĞRİLMEZ, E. D., AKMAZ, B. (2017). Clinical Features and Spectral Domain Optical Coherence Tomography Findings in Vogt- Koyanagi-Harada Syndrome: A Case Series. Retina-Vitreus, Cilt: 26 - Sayı: 0, 287–295. https://ajindex.com/articles/304892

References (17)

  1. Cunningham ET Jr, Rathinam SR, Tugal-Tutkun I, et al. Vogt-Koyanagi- Harada disease. Ocul Immunol Infl amm 2014;22:249-52
  2. Sakata VM, da Silva FT, Hirata CE, et al. Diagnosis and classification of Vogt-Koyanagi-Harada disease. Autoimmun Rev 2014;13:550-5
  3. Wang Y, Chan CC. Gender diff erences in vogt-koyanagi-harada disease and sympathetic ophthalmia. J Ophthalmol 2014;2014:157803
  4. Khairallah AS. Headache as an initial manifestation of Vogt-Koyanagi- Harada disease. Saudi J Ophthalmol. 2014;28(3):239-42
  5. Tugal-Tutkun I, Ozyazgan Y, Akova YA, et al. The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey. Int Ophthalmol 2007;27:117-23
  6. Iwahashi C, Okuno K, Hashida N, et al. Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals. Jpn J Ophthalmol 2015;59:157-63
  7. Herbort CP, Mochizuki M. Vogt–Koyanagi–Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan. Int Ophthalmol 2007;27:67–79
  8. Greco A, Fusconi M, Gallo A, Turchetta R, et al. Vogt-Koyanagi- Harada syndrome. Autoimmun Rev 2013;12:1033-8
  9. Kazokoglu H, Onal S, Tugal-Tutkun I, Mirza E, et al. Demographic and clinical features of uveitis in tertiary centers in Turkey. Ophthalmic Epidemiol 2008;15:285-93
  10. Ozdal P, Ozdamar Y, Yazici A, et al. Vogt-Koyanagi-Harada disease: clinical and demographic characteristics of patients in a specialized eye hospital in Turkey. Ocul Immunol Infl amm 2014;22:277–86
  11. Ceylan OM, Uysal Y, Türk A, ve ark. Vogt-Koyanagi-Harada Sendromlu Olguların Klinik Özellikleri. TJO 2010; 40: 250-4
  12. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 2001;131:647-52
  13. Yang P, Ren Y, Li B, et al. Clinical characteristics of Vogt-Koyanagi- Harada syndrome in Chinese patients. Ophthalmology 2007;114:606–14
  14. Rao NA, Gupta A, Dustin L, et al. Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease. Ophthalmology 2010;117:591–9
  15. Jap A, Chee SP. Imaging in the diagnosis and management of Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin 2012;52:163–72
  16. Ishihara K, Hangai M, Kita M, et al. Acute Vogt-Koyanagi-Harada disease in enhanced spectral-domain optical coherence tomography. Ophthalmology 2009;116:1799-807
  17. Maruyama Y, Kishi S. Tomographic features of serous retinal detachment in Vogt-Koyana